Plain-English translation of NCT07589257 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This clinical trial is testing a new medication called VRT106 combined with radiation therapy in adults with a rare, aggressive type of brain tumor called diffuse midline glioma or diffuse intrinsic pontine glioma. Researchers want to see if this treatment combination can slow tumor growth, manage side effects, and improve outcomes for patients who have recently been diagnosed or whose tumors have returned.
These brain tumors are very serious and difficult to treat with existing options. This medication has shown promise in early research, and doctors believe combining it with radiation may offer patients a better chance of survival and quality of life.
You likely qualify if…
You likely don't qualify if…
As a participant, you would receive the medication VRT106 while undergoing radiation therapy at one of several medical centers involved in the study. The study will monitor how well the treatment works, track any side effects, and measure how the medication moves through your body. You would need to attend regular visits for check-ups, imaging scans, and blood tests over the course of the treatment period.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China